facebook linkedin twitter

FDA Panel Endorses Lower-Dose Moderna COVID Shot for Booster

October 14, 2021by Lauren Neergaard and Matthew Perrone, Associated Press
FDA Panel Endorses Lower-Dose Moderna COVID Shot for Booster
This Wednesday, Dec. 23, 2020 photo shows a vial of the Moderna COVID-19 vaccine in the first round of staff vaccinations at a hospital in Denver. (AP Photo/David Zalubowski)

U.S. health advisers said Thursday that some Americans who received Moderna’s COVID-19 vaccine should get a half-dose booster to bolster protection against the virus.

The panel of advisers to the Food and Drug Administration voted unanimously to recommend a booster shot for seniors, adults with other health problems, jobs or living situations that put them at increased risk for COVID-19.

The recommendation is non-binding but it’s a key step toward expanding the U.S. booster campaign to millions more Americans. Many people who got their initial Pfizer shots at least six months ago are already getting a booster after the FDA authorized their use last month.

As for the dose, initial Moderna vaccination consists of two 100-microgram shots. But Moderna says a single 50-microgram shot should be enough for a booster.

The agency convened its experts Thursday and Friday to weigh-in on who should get boosters and when for people that received the Moderna and Johnson & Johnson shots earlier this year.

The FDA will use its advisers’ recommendations in making final decisions for boosters from both companies. Assuming a positive decision, there’s still another hurdle: Next week, a panel convened by the Centers for Disease Control and Prevention will offer more specifics on who should get one.

THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.

U.S. health advisers are debating if millions of Americans who received Moderna vaccinations should get a booster shot — this time, using half the original dose.

Already millions who got their initial Pfizer shots at least six months ago are getting a booster of that brand. Thursday, advisers to the Food and Drug Administration evaluated the evidence that Moderna boosters should be offered, too — and on Friday, they’ll tackle the same question for those who got Johnson & Johnson’s vaccine.

U.S. officials stress that the priority is to get shots to the 66 million unvaccinated Americans who are eligible for immunization — those most at risk as the extra-contagious delta variant of the coronavirus has burned across the country.

“It’s important to remember that the vaccines still provide strong protection against serious outcomes” such as hospitalization and death from COVID-19, said FDA vaccine chief Dr. Peter Marks.

But Marks said it’s also become clear there is some waning of protection against milder infections with all three of the coronavirus vaccines used in the U.S. And he encouraged the advisory panel to consider if the evidence backs similar booster recommendations for all of them as well, since that would “create the least confusion” for the public.

Moderna is seeking FDA clearance for a booster used just like Pfizer’s: For people 65 and older, or adults with other health problems, jobs or living situations that put them at increased risk of serious coronavirus — once they are at least six months past their last dose.

The FDA will use its advisers’ recommendations in deciding whether to authorize Moderna boosters. If it does, there’s still another hurdle: Next week, a panel convened by the Centers for Disease Control and Prevention will offer more specifics on who should get one.

What’s the evidence that the Moderna vaccine’s protection is waning? As the delta variant surged in July and August, people who were more recently vaccinated had a 36% lower rate of “breakthrough” infections compared with those vaccinated longer ago, Moderna’s Dr. Jacqueline Miller told FDA’s advisers.

As for the dose, initial Moderna vaccination consists of two 100-microgram shots. But Moderna says a single 50-microgram shot should be enough for a booster. The company said that would trigger fewer uncomfortable shot reactions such as fever and achiness while also leaving more vaccine available for the global supply.

A study of 344 people found the booster shot six months after initial vaccinations restored virus-fighting antibodies to levels seen after recipients’ last dose — and that included large jumps in antibodies able to target the delta variant, Miller said.

One very rare side effect of both the Moderna and Pfizer vaccines is heart inflammation, particularly among young men soon after the second dose — and one lingering question is whether another dose could spark more cases. Moderna’s booster study wasn’t large enough to spot such a rare risk.

But Israel began offering Pfizer boosters sooner than the U.S. and to more of its population. Thursday, Dr. Sharon Alroy-Preis of Israel’s health ministry told the FDA panel that after 3.7 million booster doses administered, there’s no sign the extra shot is any riskier — despite an intense investigation into heart inflammation.

In the U.S., scientists are divided about exactly who needs boosters and their purpose — whether they’re needed mostly for people at risk of severe disease or whether they should be used to try to reduce milder infections, too. While Pfizer’s boosters are only for certain high-risk groups of Americans, Israeli officials credit wider booster use in their country to stemming the delta surge.

“There is no question in my mind that the break of the curve was due to the booster dose,” Alroy-Preis said in response to FDA advisers who noted that other countries have seen a lowering of delta cases without widespread booster use.

As Thursday’s deliberations began, FDA’s advisers highlighted one confusing issue: People with severely weakened immune systems already can get a third full dose of the Moderna vaccine soon after the initial vaccinations — so a question is whether they should be eligible for a booster, too, which would be their fourth dose.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

A+
a-

In The News

Health

Voting

Health

January 24, 2022
by Tom Ramstack
Sarah Palin Diagnosed With COVID Before New York Times Lawsuit Trial

NEW YORK — Former vice-presidential candidate Sarah Palin was diagnosed with COVID-19 this weekend, which delayed her defamation lawsuit against... Read More

NEW YORK — Former vice-presidential candidate Sarah Palin was diagnosed with COVID-19 this weekend, which delayed her defamation lawsuit against The New York Times that was scheduled for a trial beginning Monday. Palin reported her illness to Judge Jed Rakoff of the U.S. District Court in... Read More

January 24, 2022
by Reece Nations
Political Polarization Impeded Public Support for COVID-19 Response

SAN ANTONIO — Public sentiment regarding COVID-19 mitigation strategies was undermined by polarization from political actors around the globe, according... Read More

SAN ANTONIO — Public sentiment regarding COVID-19 mitigation strategies was undermined by polarization from political actors around the globe, according to new research published in the Proceedings of the National Academy of Sciences. Researchers from around the world contributed to the study which examined the effects... Read More

January 24, 2022
by Tom Ramstack
FBI Cracks Down on Organizations Accused of Cashing In on the Pandemic

WASHINGTON —  The FBI is investigating an Illinois company that has received $124 million from the federal government for COVID-19... Read More

WASHINGTON —  The FBI is investigating an Illinois company that has received $124 million from the federal government for COVID-19 testing after reports the owners were using part of the money for lavish lifestyles. FBI agents raided the headquarters in Rolling Meadows, Illinois, Saturday. It opened... Read More

New Conservative Target: Race as Factor in COVID Treatment

MADISON, Wis. (AP) — Some conservatives are taking aim at policies that allow doctors to consider race as a risk... Read More

MADISON, Wis. (AP) — Some conservatives are taking aim at policies that allow doctors to consider race as a risk factor when allocating scarce COVID-19 treatments, saying the protocols discriminate against white people. The wave of infections brought on by the omicron variant and a shortage of... Read More

China Tests 2M in Beijing, Lifts COVID Lockdown in Xi’an

BEIJING (AP) — A cluster of COVID-19 cases in Beijing has prompted authorities to test millions and impose new measures... Read More

BEIJING (AP) — A cluster of COVID-19 cases in Beijing has prompted authorities to test millions and impose new measures two weeks ahead of the opening of the Winter Olympics, even as the city of Xi'an in north-central China lifted on Monday a monthlong lockdown that... Read More

US Jobless Claims Rise to 286,000, Highest Since October

WASHINGTON (AP) — The number of Americans applying for unemployment benefits rose to the highest level in three months as... Read More

WASHINGTON (AP) — The number of Americans applying for unemployment benefits rose to the highest level in three months as the fast-spreading omicron variant continued to disrupt the job market. Jobless claims rose for the third straight week — by 55,000 to 286,000, highest since mid-October,... Read More

News From The Well
scroll top